Kathryn Colborn
Concepts (462)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 14 | 2025 | 1196 | 3.930 |
Why?
| | Postoperative Complications | 34 | 2026 | 2970 | 2.920 |
Why?
| | Machine Learning | 11 | 2026 | 587 | 2.280 |
Why?
| | Surgical Wound Infection | 8 | 2025 | 329 | 1.830 |
Why?
| | Models, Statistical | 6 | 2026 | 671 | 1.580 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 210 | 1.330 |
Why?
| | Surgical Procedures, Operative | 6 | 2025 | 271 | 1.320 |
Why?
| | Sepsis | 7 | 2025 | 664 | 1.310 |
Why?
| | Shock, Septic | 5 | 2025 | 227 | 1.280 |
Why?
| | Pancreatic Neoplasms | 11 | 2025 | 928 | 1.200 |
Why?
| | Quality Improvement | 14 | 2023 | 1295 | 1.150 |
Why?
| | Malaria | 4 | 2023 | 72 | 1.000 |
Why?
| | Quality of Life | 14 | 2026 | 3204 | 0.950 |
Why?
| | Law Enforcement | 1 | 2025 | 48 | 0.900 |
Why?
| | Police | 1 | 2025 | 45 | 0.890 |
Why?
| | Retrospective Studies | 51 | 2026 | 17291 | 0.890 |
Why?
| | Humans | 140 | 2026 | 145475 | 0.840 |
Why?
| | Databases, Factual | 16 | 2025 | 1490 | 0.730 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 105 | 0.720 |
Why?
| | Risk Assessment | 20 | 2026 | 3747 | 0.720 |
Why?
| | Pneumonia | 4 | 2025 | 636 | 0.720 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 32 | 0.710 |
Why?
| | Palliative Care | 10 | 2026 | 1020 | 0.680 |
Why?
| | Emergency Service, Hospital | 5 | 2025 | 2381 | 0.670 |
Why?
| | Breast Neoplasms | 8 | 2026 | 2382 | 0.640 |
Why?
| | Plasmodium vivax | 2 | 2018 | 6 | 0.640 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.640 |
Why?
| | Pain | 2 | 2023 | 789 | 0.640 |
Why?
| | Middle Aged | 47 | 2026 | 36215 | 0.620 |
Why?
| | Aged | 39 | 2026 | 26153 | 0.620 |
Why?
| | Female | 69 | 2026 | 78845 | 0.610 |
Why?
| | Adenocarcinoma | 5 | 2024 | 925 | 0.610 |
Why?
| | Preoperative Care | 5 | 2026 | 380 | 0.570 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 497 | 0.570 |
Why?
| | Male | 61 | 2026 | 72843 | 0.570 |
Why?
| | Surgeons | 4 | 2025 | 340 | 0.560 |
Why?
| | Inpatients | 4 | 2023 | 553 | 0.540 |
Why?
| | Artificial Intelligence | 1 | 2023 | 381 | 0.540 |
Why?
| | Mastectomy | 5 | 2026 | 184 | 0.540 |
Why?
| | Poisson Distribution | 1 | 2018 | 78 | 0.530 |
Why?
| | Thoracic Surgery | 3 | 2025 | 143 | 0.530 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 37 | 0.530 |
Why?
| | Health Plan Implementation | 1 | 2019 | 141 | 0.530 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 465 | 0.510 |
Why?
| | Risk Factors | 26 | 2026 | 10885 | 0.510 |
Why?
| | Adult | 42 | 2026 | 40777 | 0.500 |
Why?
| | Mosquito Control | 2 | 2023 | 30 | 0.490 |
Why?
| | Hospitalization | 7 | 2025 | 2460 | 0.490 |
Why?
| | Algorithms | 5 | 2025 | 1845 | 0.460 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.450 |
Why?
| | Child, Preschool | 19 | 2026 | 11853 | 0.450 |
Why?
| | Anopheles | 1 | 2015 | 18 | 0.440 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 293 | 0.430 |
Why?
| | Drug Prescriptions | 3 | 2021 | 288 | 0.410 |
Why?
| | Risk Adjustment | 2 | 2025 | 85 | 0.410 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 390 | 0.400 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 94 | 0.370 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 107 | 0.370 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 79 | 0.360 |
Why?
| | Primary Health Care | 3 | 2025 | 1735 | 0.360 |
Why?
| | Patient Discharge | 2 | 2020 | 992 | 0.360 |
Why?
| | Hospital Mortality | 1 | 2016 | 1038 | 0.350 |
Why?
| | Decision Support Systems, Clinical | 2 | 2026 | 272 | 0.340 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 115 | 0.330 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 185 | 0.330 |
Why?
| | Infant | 14 | 2026 | 10077 | 0.330 |
Why?
| | Influenza, Human | 3 | 2021 | 624 | 0.310 |
Why?
| | Incidence | 8 | 2023 | 2923 | 0.310 |
Why?
| | Hospitals | 4 | 2025 | 732 | 0.300 |
Why?
| | Emergency Treatment | 2 | 2021 | 123 | 0.300 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 602 | 0.300 |
Why?
| | Zebrafish | 2 | 2025 | 532 | 0.290 |
Why?
| | Heart Failure | 5 | 2025 | 2326 | 0.290 |
Why?
| | Pancreatectomy | 4 | 2025 | 289 | 0.290 |
Why?
| | Colorado | 9 | 2025 | 4554 | 0.290 |
Why?
| | United States | 20 | 2025 | 16098 | 0.280 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8333 | 0.280 |
Why?
| | Research Design | 3 | 2022 | 1137 | 0.260 |
Why?
| | Cohort Studies | 11 | 2024 | 6013 | 0.260 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2953 | 0.260 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 280 | 0.260 |
Why?
| | Adolescent | 16 | 2026 | 22530 | 0.260 |
Why?
| | Logistic Models | 5 | 2023 | 2134 | 0.250 |
Why?
| | Preoperative Period | 2 | 2025 | 149 | 0.250 |
Why?
| | Chagas Disease | 2 | 2018 | 42 | 0.250 |
Why?
| | Patient Satisfaction | 4 | 2024 | 709 | 0.250 |
Why?
| | Seasons | 3 | 2025 | 538 | 0.250 |
Why?
| | Asthma | 1 | 2019 | 1797 | 0.250 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 610 | 0.250 |
Why?
| | Proportional Hazards Models | 3 | 2026 | 1327 | 0.250 |
Why?
| | Child | 16 | 2026 | 22707 | 0.250 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 422 | 0.240 |
Why?
| | Prognosis | 10 | 2024 | 4316 | 0.240 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.240 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 159 | 0.240 |
Why?
| | Bayes Theorem | 2 | 2026 | 420 | 0.240 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 374 | 0.230 |
Why?
| | Varenicline | 1 | 2025 | 28 | 0.230 |
Why?
| | Monte Carlo Method | 1 | 2026 | 147 | 0.230 |
Why?
| | Markov Chains | 1 | 2026 | 132 | 0.230 |
Why?
| | Survival Analysis | 2 | 2026 | 1374 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.220 |
Why?
| | Intracranial Pressure | 1 | 2026 | 65 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 423 | 0.220 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 202 | 0.220 |
Why?
| | Time-to-Treatment | 2 | 2025 | 251 | 0.220 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 78 | 0.220 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 34 | 0.210 |
Why?
| | Varicose Veins | 1 | 2024 | 16 | 0.210 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 120 | 0.210 |
Why?
| | Treatment Outcome | 13 | 2025 | 11772 | 0.200 |
Why?
| | Artemisinins | 2 | 2023 | 5 | 0.200 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 910 | 0.200 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
| | Specialties, Surgical | 2 | 2021 | 82 | 0.190 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 39 | 0.190 |
Why?
| | Zebrafish Proteins | 2 | 2025 | 314 | 0.190 |
Why?
| | Hypothermia | 1 | 2023 | 53 | 0.190 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1547 | 0.190 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 36 | 0.190 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 2121 | 0.190 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 64 | 0.190 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 51 | 0.190 |
Why?
| | Behavior Therapy | 1 | 2025 | 296 | 0.180 |
Why?
| | Insecticides | 1 | 2023 | 44 | 0.180 |
Why?
| | Patient Participation | 1 | 2026 | 439 | 0.180 |
Why?
| | Europe | 1 | 2023 | 418 | 0.180 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 71 | 0.180 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 1149 | 0.180 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 73 | 0.180 |
Why?
| | Telemetry | 1 | 2022 | 40 | 0.180 |
Why?
| | Medication Therapy Management | 1 | 2023 | 72 | 0.180 |
Why?
| | Nervous System Diseases | 1 | 2025 | 286 | 0.180 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 49 | 0.180 |
Why?
| | Microcephaly | 1 | 2023 | 104 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1371 | 0.180 |
Why?
| | Young Adult | 11 | 2020 | 14219 | 0.180 |
Why?
| | Syncope | 1 | 2022 | 56 | 0.180 |
Why?
| | Polypharmacy | 1 | 2023 | 94 | 0.180 |
Why?
| | Quinolines | 2 | 2023 | 190 | 0.180 |
Why?
| | Hospitals, Pediatric | 1 | 2025 | 558 | 0.180 |
Why?
| | Carotid Stenosis | 1 | 2023 | 107 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 224 | 0.180 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 44 | 0.180 |
Why?
| | Anti-Bacterial Agents | 4 | 2025 | 1923 | 0.180 |
Why?
| | Galectins | 1 | 2022 | 26 | 0.180 |
Why?
| | Decision Support Techniques | 1 | 2026 | 477 | 0.170 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 90 | 0.170 |
Why?
| | Pneumonectomy | 1 | 2023 | 167 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 440 | 0.170 |
Why?
| | Ivermectin | 1 | 2021 | 15 | 0.170 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 105 | 0.170 |
Why?
| | Computer Simulation | 1 | 2026 | 1003 | 0.170 |
Why?
| | Precision Medicine | 1 | 2025 | 459 | 0.170 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 119 | 0.170 |
Why?
| | Program Evaluation | 3 | 2021 | 943 | 0.160 |
Why?
| | Dysbiosis | 1 | 2022 | 187 | 0.160 |
Why?
| | Oxycodone | 1 | 2021 | 52 | 0.160 |
Why?
| | New Guinea | 2 | 2018 | 3 | 0.160 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 22 | 0.160 |
Why?
| | Internet | 1 | 2025 | 689 | 0.160 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 343 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 609 | 0.160 |
Why?
| | Communication | 2 | 2025 | 975 | 0.160 |
Why?
| | Knee Joint | 2 | 2021 | 428 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2022 | 126 | 0.160 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 716 | 0.160 |
Why?
| | Arthroplasty | 1 | 2020 | 59 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 254 | 0.160 |
Why?
| | Faculty | 1 | 2021 | 147 | 0.150 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 48 | 0.150 |
Why?
| | Qualitative Research | 2 | 2025 | 1674 | 0.150 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 248 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2025 | 1747 | 0.150 |
Why?
| | Phenotype | 2 | 2025 | 3155 | 0.150 |
Why?
| | Brain Injuries, Traumatic | 1 | 2026 | 453 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1963 | 0.150 |
Why?
| | Terminal Care | 1 | 2023 | 283 | 0.150 |
Why?
| | Antimalarials | 1 | 2019 | 35 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 142 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 232 | 0.150 |
Why?
| | Telemedicine | 2 | 2025 | 961 | 0.150 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 70 | 0.140 |
Why?
| | Waiting Lists | 2 | 2021 | 266 | 0.140 |
Why?
| | Prisons | 1 | 2010 | 85 | 0.140 |
Why?
| | Vaccination | 2 | 2025 | 1426 | 0.140 |
Why?
| | Intensive Care Units | 2 | 2022 | 924 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 88 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 222 | 0.140 |
Why?
| | Laparoscopy | 1 | 2023 | 481 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2021 | 251 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2019 | 118 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 328 | 0.140 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 207 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1581 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 881 | 0.140 |
Why?
| | Social Marketing | 1 | 2008 | 15 | 0.140 |
Why?
| | Healthcare Disparities | 3 | 2025 | 735 | 0.140 |
Why?
| | Ventricular Function | 1 | 2018 | 53 | 0.140 |
Why?
| | Prospective Studies | 7 | 2026 | 8057 | 0.140 |
Why?
| | Hospitals, University | 1 | 2018 | 176 | 0.140 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 40 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.140 |
Why?
| | General Surgery | 1 | 2021 | 206 | 0.140 |
Why?
| | Community Participation | 1 | 2019 | 123 | 0.140 |
Why?
| | Outpatients | 1 | 2022 | 447 | 0.140 |
Why?
| | Triage | 1 | 2021 | 250 | 0.140 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 382 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 443 | 0.130 |
Why?
| | Computers, Handheld | 1 | 2018 | 26 | 0.130 |
Why?
| | Climate | 1 | 2018 | 77 | 0.130 |
Why?
| | Reproductive Medicine | 1 | 2008 | 18 | 0.130 |
Why?
| | Population Groups | 1 | 2018 | 56 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 172 | 0.130 |
Why?
| | Rural Population | 2 | 2020 | 659 | 0.130 |
Why?
| | Obesity, Morbid | 1 | 2022 | 293 | 0.130 |
Why?
| | Autistic Disorder | 1 | 2020 | 219 | 0.130 |
Why?
| | Geography | 1 | 2018 | 187 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1266 | 0.130 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 46 | 0.130 |
Why?
| | Condoms | 1 | 2008 | 102 | 0.130 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 101 | 0.130 |
Why?
| | Immunoglobulin A | 1 | 2019 | 214 | 0.130 |
Why?
| | Patient Admission | 1 | 2019 | 220 | 0.130 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 117 | 0.130 |
Why?
| | ROC Curve | 1 | 2019 | 617 | 0.130 |
Why?
| | Safety-net Providers | 1 | 2019 | 130 | 0.130 |
Why?
| | Burns | 1 | 2022 | 374 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 587 | 0.130 |
Why?
| | Recovery of Function | 1 | 2021 | 716 | 0.130 |
Why?
| | Occupational Health | 1 | 2010 | 211 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2023 | 173 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 345 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 96 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2017 | 63 | 0.120 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 127 | 0.120 |
Why?
| | Anxiety Disorders | 1 | 2010 | 369 | 0.120 |
Why?
| | Cell Phone | 1 | 2017 | 82 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2021 | 534 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 74 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 378 | 0.120 |
Why?
| | HIV Infections | 2 | 2025 | 3194 | 0.120 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 499 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 103 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2010 | 355 | 0.120 |
Why?
| | Parents | 1 | 2025 | 1403 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 390 | 0.120 |
Why?
| | Fever | 1 | 2017 | 319 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 759 | 0.120 |
Why?
| | Patient Readmission | 2 | 2020 | 769 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 822 | 0.120 |
Why?
| | Nurse Practitioners | 1 | 2018 | 139 | 0.120 |
Why?
| | Models, Organizational | 1 | 2016 | 144 | 0.110 |
Why?
| | Morbidity | 3 | 2022 | 322 | 0.110 |
Why?
| | Surveys and Questionnaires | 6 | 2026 | 6066 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5423 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2025 | 1161 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 849 | 0.110 |
Why?
| | Humidity | 1 | 2015 | 49 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 890 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 199 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 674 | 0.110 |
Why?
| | Diarrhea | 3 | 2023 | 193 | 0.110 |
Why?
| | Massage | 2 | 2010 | 42 | 0.110 |
Why?
| | Mass Screening | 2 | 2020 | 1360 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 407 | 0.100 |
Why?
| | Pandemics | 4 | 2025 | 1707 | 0.100 |
Why?
| | Advance Care Planning | 1 | 2018 | 244 | 0.100 |
Why?
| | Cannabidiol | 1 | 2016 | 142 | 0.100 |
Why?
| | Anticonvulsants | 1 | 2016 | 246 | 0.100 |
Why?
| | Time Factors | 5 | 2024 | 7123 | 0.100 |
Why?
| | Stroke | 1 | 2023 | 1270 | 0.100 |
Why?
| | Indians, North American | 1 | 2009 | 597 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1764 | 0.100 |
Why?
| | Survival Rate | 3 | 2024 | 2090 | 0.100 |
Why?
| | Neoplasms | 2 | 2025 | 2906 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1997 | 0.100 |
Why?
| | Parasitemia | 1 | 2013 | 15 | 0.100 |
Why?
| | Emergency Medical Services | 1 | 2021 | 684 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 558 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 578 | 0.100 |
Why?
| | Research | 1 | 2016 | 430 | 0.100 |
Why?
| | Chronic Pain | 1 | 2018 | 291 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1210 | 0.090 |
Why?
| | Software | 1 | 2018 | 680 | 0.090 |
Why?
| | Medicaid | 1 | 2017 | 467 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 568 | 0.090 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 107 | 0.090 |
Why?
| | Axilla | 2 | 2023 | 51 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 633 | 0.090 |
Why?
| | Washington | 2 | 2025 | 149 | 0.090 |
Why?
| | Emergencies | 2 | 2025 | 174 | 0.090 |
Why?
| | Epilepsy | 1 | 2016 | 390 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 180 | 0.090 |
Why?
| | Patients | 2 | 2023 | 183 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 412 | 0.090 |
Why?
| | Uganda | 2 | 2023 | 89 | 0.080 |
Why?
| | Age Factors | 4 | 2021 | 3342 | 0.080 |
Why?
| | Prevalence | 3 | 2023 | 2865 | 0.080 |
Why?
| | Pain Management | 2 | 2010 | 410 | 0.080 |
Why?
| | Disease Progression | 1 | 2019 | 2864 | 0.080 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 331 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2930 | 0.080 |
Why?
| | Neoplasm Staging | 2 | 2025 | 1471 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 680 | 0.080 |
Why?
| | Internship and Residency | 1 | 2021 | 1267 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 110 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 351 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2214 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2664 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 946 | 0.070 |
Why?
| | Guatemala | 2 | 2023 | 343 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 899 | 0.070 |
Why?
| | Lymph Nodes | 2 | 2023 | 503 | 0.070 |
Why?
| | Administration, Oral | 2 | 2025 | 866 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2015 | 690 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 912 | 0.070 |
Why?
| | Piperazines | 2 | 2023 | 375 | 0.070 |
Why?
| | Biomedical Research | 2 | 2025 | 717 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2024 | 586 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 193 | 0.060 |
Why?
| | Echocardiography | 2 | 2022 | 647 | 0.060 |
Why?
| | Comorbidity | 2 | 2022 | 1661 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 221 | 0.060 |
Why?
| | Urban Population | 2 | 2020 | 493 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 244 | 0.060 |
Why?
| | Length of Stay | 2 | 2023 | 1349 | 0.060 |
Why?
| | Nebraska | 1 | 2025 | 21 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2023 | 867 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 27 | 0.060 |
Why?
| | Affect | 1 | 2008 | 320 | 0.060 |
Why?
| | India | 1 | 2025 | 213 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1891 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2025 | 172 | 0.050 |
Why?
| | Glasgow Coma Scale | 1 | 2026 | 218 | 0.050 |
Why?
| | Cytokines | 2 | 2023 | 2067 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1323 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2022 | 6447 | 0.050 |
Why?
| | Acute Disease | 2 | 2017 | 1036 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5905 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 377 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2010 | 536 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2445 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2026 | 288 | 0.050 |
Why?
| | Animals | 4 | 2025 | 38030 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 222 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 121 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2023 | 133 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 25 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 89 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 76 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 85 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 21 | 0.050 |
Why?
| | Death | 1 | 2023 | 132 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 639 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 10 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 131 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 41 | 0.050 |
Why?
| | Breast | 1 | 2023 | 156 | 0.050 |
Why?
| | Alleles | 1 | 2025 | 894 | 0.050 |
Why?
| | Community Health Workers | 1 | 2023 | 88 | 0.050 |
Why?
| | Cough | 1 | 2023 | 124 | 0.050 |
Why?
| | Cardiology | 1 | 2025 | 362 | 0.040 |
Why?
| | Stroke Volume | 1 | 2025 | 654 | 0.040 |
Why?
| | Carotid Arteries | 1 | 2023 | 208 | 0.040 |
Why?
| | Patient Acuity | 1 | 2022 | 48 | 0.040 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 104 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2023 | 767 | 0.040 |
Why?
| | Demography | 1 | 2022 | 282 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 466 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 202 | 0.040 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 66 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 121 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 665 | 0.040 |
Why?
| | Habits | 1 | 2020 | 52 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 239 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 184 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 569 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 33 | 0.040 |
Why?
| | Gastrectomy | 1 | 2022 | 166 | 0.040 |
Why?
| | Policy | 1 | 2021 | 148 | 0.040 |
Why?
| | Lung | 2 | 2024 | 4106 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 159 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1266 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 239 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 500 | 0.040 |
Why?
| | Fear | 1 | 2023 | 368 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 266 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 633 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 251 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 50 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 15 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 12 | 0.040 |
Why?
| | Risk | 1 | 2022 | 919 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 65 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 368 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 217 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 98 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 527 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 506 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 129 | 0.030 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 5 | 0.030 |
Why?
| | Colombia | 1 | 2018 | 42 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 523 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2010 | 266 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 159 | 0.030 |
Why?
| | Fluorouracil | 1 | 2019 | 231 | 0.030 |
Why?
| | Drug Combinations | 1 | 2019 | 396 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 258 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2023 | 547 | 0.030 |
Why?
| | Overweight | 1 | 2023 | 614 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1808 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 429 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 182 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1321 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 558 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 143 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1082 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 378 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 6 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 16 | 0.030 |
Why?
| | Caregivers | 1 | 2025 | 1073 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 526 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 96 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 900 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1149 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 142 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 793 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 354 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 858 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 484 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 288 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 132 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 168 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1118 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 832 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 149 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 390 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 188 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 665 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 845 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 572 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1734 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 4075 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 969 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 1070 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 310 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 822 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3623 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3413 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2105 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 775 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2878 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4295 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2406 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3116 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 318 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1635 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 1101 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|